GE Healthcare announces FDA approval of Vizamyl

October 25, 2013

GE Healthcare announced the U.S. FDA approval of Vizamyl, a radioactive diagnostic agent indicated for Positron Emission Tomography imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of cognitive decline. Vizamyl is an adjunct to other diagnostic evaluations. Vizamyl is the only PET imaging tracer for detection of amyloid approved by FDA for visual interpretation of color images rather than black and white assessment, and will be commercially available in 2014.